BG
Bellevue Group Portfolio holdings
AUM
$4.81B
1-Year Est. Return
29.28%
1 Year Est. Return
+29.28%
AUM
$4.81B
AUM Growth
+$276M
(+6.1%)
Holding
159
Top Buys
| 1 | +$93.8M | |
| 2 | +$46.4M | |
| 3 | +$25.1M | |
| 4 |
Akero Therapeutics
AKRO
|
+$19.2M |
| 5 |
Immunocore
IMCR
|
+$12.9M |
Top Sells
| 1 | +$105M | |
| 2 | +$105M | |
| 3 | +$36.5M | |
| 4 |
Moderna
MRNA
|
+$31.8M |
| 5 |
Stryker
SYK
|
+$31M |
Sector Composition
| 1 | Healthcare | 99.85% |
| 2 | Technology | 0.03% |
| 3 | Consumer Discretionary | 0.02% |
| 4 | Communication Services | 0.02% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Arcutis Biotherapeutics
ARQT
$3.72B
| – | – |
-24,008
|
|
||
152
Black Diamond Therapeutics
BDTX
$215M
| – | – |
-2,733,547
|
|
||
|
BPMC
153
DELISTED
Blueprint Medicines
BPMC
| – | – |
-284,900
|
|
||
154
BellRing Brands
BRBR
$3.7B
| – | – |
-3,500
|
|
||
155
Novo Nordisk
NVO
$215B
| – | – |
-6,500
|
|
||
156
Oculis Holding
OCS
$1.1B
| – | – |
-9,700
|
|
||
157
Travere Therapeutics
TVTX
$3.15B
| – | – |
-18,303
|
|
||
|
VRNA
158
DELISTED
Verona Pharma
VRNA
| – | – |
-15,927
|
|
||
|
MTSR
159
DELISTED
Metsera Inc
MTSR
| – | – |
-7,800
|
|